| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c821adab4a045b72f43449186b20dfba |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fff32576d5f761993237ba8b2e7d3d1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ecdec876d0a1f49853a3174ce84b82b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd67b68f36acf50707cf67cb9a967c1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4e4c1b070afed4892ebee77d99929f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1954089c57cb47d279bc987cab1a1343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_090ce1a9efa88a5b8196749e6392171a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e6e2e0001724c2068593eaeba01b1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f119a28c8aff683078aa9ecdf72bb0e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6574a4d11e90d8340ee09a4ad75f12fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ad416b76061b508c044bacbeca324e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e929bab0360a988eb5a7ecde6fbc7a57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ce1d50674103da7a8f164d6116c6fa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34fa62dc7762fd95a30be94917e8646a |
| publicationDate |
2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103060330-B |
| titleOfInvention |
Kit for predicting susceptibility to prostate cancer |
| abstract |
The invention discloses a reagent and a method for predicting susceptibility to prostate cancer, belonging to the field of biotechnology. The reagent and the method can be used for predicting susceptibility of a subject to prostate cancer by extracting the genomic deoxyribonucleic acid (DNA) of host cells and testing the genotype of the rs6901250 site on the sixth exon of GPRC 6A gene of the subject; when the genotype of the rs6901250 on the sixth exon of the GPRC 6A gene is AA, the susceptibility of the subject to prostate cancer is the highest; and when the genotype of the rs6901250 is AG or GG, the susceptibility of the subject to prostate cancer is lower. The reagent and the method have the advantages that the correlation between rs6901250 gene polymorphic site and prostate cancer is expounded for the first time; the method for predicting the susceptibility to prostate cancer is provided; and the method can be used for early prevention diagnosis and auxiliary diagnosis of prostate cancer, and is also used for research and development of new medicines. |
| priorityDate |
2012-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |